NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers
Data To Be Presented At AAIC In July
Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.
